List view / Grid view
16 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes...
12 September 2014 | By Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19...
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
5 September 2014 | By Abbott
Abbott announced that it has received CE Mark for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes...
2 September 2014 | By Daiichi Sankyo
A SGLT2 inhibitor for Type2 Diabetes Mellitus...
1 September 2014 | By Novo Nordisk
Novo Nordisk announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes...
12 August 2014 | By Sanofi
Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder...
11 August 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration has approved INVOKAMET™, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes...
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). More than 25 million Americans are…
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
